Entasis Therapeutics Appoints Dr. David Altarac as Chief Medical Officer
30 oct. 2019 16h05 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat...
BioAegis Therapeutics Named New Jersey’s Most Valuable Venture-Backed Company Led by a Woman
22 oct. 2019 16h53 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., Oct. 22, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics was recently recognized by PitchBook as the most valuable venture-backed company in New Jersey led by a female entrepreneur....
BioAegis Therapeutics Announces Publication in the Journal of Infectious Diseases: "Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Penicillin-Sensitive and Resistant Pneumococcal Pneumonia"
22 août 2019 10h15 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., Aug. 22, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing technology to control inflammation while protecting immune function and vital...
BioAegis Therapeutics Reports Favorable Safety and Pharmacokinetic Results in its Phase 1b/2a Dose-Escalation Study of Recombinant Human Plasma Gelsolin with Highest Doses Ever Administered to Patients
07 août 2019 10h00 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc. announced the major findings from its Phase 1b/2a study of Recombinant Human Plasma Gelsolin for patients requiring...
Phase Genomics’ Platform Links Viruses and Antibiotic Resistance Genes to the Microbiome in Study of a Highly Complex Microbial Community
06 août 2019 09h15 HE
|
Phase Genomics
SEATTLE, Washington, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Phase Genomics, Inc., the leading provider of proximity ligation next generation sequencing (NGS) solutions for genomics and metagenomics, in...
Entasis Therapeutics Announces New Results Supporting Advancement of Multiple Pathogen-Targeted Antimicrobial Programs at ASM Microbe 2019
27 juin 2019 08h00 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Phase Genomics Accelerates Microbiome Discovery and Antibiotic Resistance tracking with New ProxiMeta™ 8-Pack Including Bundled Analysis
20 juin 2019 09h05 HE
|
Phase Genomics
SEATTLE, Washington, June 20, 2019 (GLOBE NEWSWIRE) -- Phase Genomics, Inc., the biotech leader providing proximity ligation solutions for genome and metagenome assembly, announces its new...
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019
12 juin 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019 Oxford, UK,...
Entasis Therapeutics Announces Oral and Poster Presentations of its Pathogen-Targeted Antibiotic Clinical Programs at ASM Microbe 2019
10 juin 2019 08h00 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., June 10, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
DNV GL Healthcare Focuses on Overcoming Antimicrobial Resistance in Nation's Hospitals
29 mai 2019 16h27 HE
|
DNV GL Business Assurance USA, Inc.
MILFORD, OHIO, May 29, 2019 (GLOBE NEWSWIRE) -- As the Centers for Disease Control and Prevention (CDC) ramps up the nation’s attempts to neutralize antibiotic/anti-microbial resistance (AMR) in...